(Q46394309)

21 December 2017

title

Can we improve the performance and reporting of investigator-initiated clinical trials? Rheumatoid arthritis as an example (English)

1 reference

21 December 2017

1 reference

Désirée van der Heijde

9

Désirée van der Heijde

0 references

Paul Emery

4

Paul Emery

0 references

Maxime Dougados

5

Maxime Dougados

1 reference

21 December 2017

2

Josef S Smolen

1 reference

21 December 2017

7

Daniel Aletaha

1 reference

21 December 2017

Michael E Weinblatt

3

Michael E Weinblatt

1 reference

21 December 2017

Robert Landewé

1

Robert B M Landewé

1 reference

21 December 2017

Roy Fleischmann

6

Roy Fleischmann

1 reference

21 December 2017

Arthur Kavanaugh

8

Arthur Kavanaugh

1 reference

21 December 2017

language of work or name

English

0 references

publication date

11 August 2014

1 reference

21 December 2017

Annals of the Rheumatic Diseases

published in

1 reference

21 December 2017

volume

73

1 reference

21 December 2017

issue

10

1 reference

21 December 2017

page(s)

1755-1760

1 reference

21 December 2017

The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials

cites work

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

A simplified disease activity index for rheumatoid arthritis for use in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

Definition of treatment response in rheumatoid arthritis based on the simplified and the clinical disease activity index

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

How to report radiographic data in randomized clinical trials in rheumatoid arthritis: guidelines from a roundtable discussion

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

Proposal for a new nomenclature of disease-modifying antirheumatic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

Therapies for active rheumatoid arthritis after methotrexate failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

Treating rheumatoid arthritis to target: recommendations of an international task force

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

Reporting noninferiority trials--reply

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

Comparative effectiveness research: a report from the Institute of Medicine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205821

10.1136/ANNRHEUMDIS-2014-205821

21 January 2018

Identifiers

DOI

1 reference

21 December 2017

Dimensions Publication ID

0 references

1 reference

21 December 2017